| 潘承欣 崔仁忠 吴绮鋆 张秀容 崔琦 邹礼明 杨接辉.曲妥珠单抗联合NSC 74859 对曲妥珠耐药的乳腺癌细胞的抑制作用研究[J].,2016,16(7):1253-1256 |
| 曲妥珠单抗联合NSC 74859 对曲妥珠耐药的乳腺癌细胞的抑制作用研究 |
| Study in the Effects of Trastuzumab and NSC78459 on InhibitingTrastuzumab-resistant Human Breast Cancer Cells |
| |
| DOI： |
| 中文关键词: 曲妥珠单抗 NSC 74859 曲妥珠耐药 乳腺癌 SK-BR-3R细胞 |
| 英文关键词: Trastuzumab NSC 74859 Trastuzumab resistance Breast cancer SK-BR-3R cell line |
| 基金项目: |
|
| 摘要点击次数: 1054 |
| 全文下载次数: 4 |
| 中文摘要: |
| 目的：观察曲妥珠单抗(Trastuzumab)与转录信号转导子与激活子3 蛋白（STAT3）抑制剂NSC 74859 联用对曲妥珠耐药细
胞株SK-BR-3R的生长抑制作用及机理研究。方法：采用四甲基偶氮唑蓝（MTT）法鉴定曲妥珠耐药的SK-BR-3R细胞株并检测曲
妥珠单药处理、NSC 74859 单药处理以及两药联用处理对SK-BR-3R细胞的生长抑制程度。建立SK-BR-3R的皮下肿瘤模型，观
察两药联用对肿瘤生长的抑制效果；通过免疫印迹(Western Blot)实验检测SK-BR-3R 细胞中磷酸化HER2(p-HER2)，磷酸化
STAT3(p-STAT3)及磷酸化AKT(p-AKT)的水平。结果：当曲妥珠浓度在50 nmol/L 及NSC 74859 的浓度在50 滋mol/L联用时，较
之两药单用显示了显著的抑制效果，其差异具有统计学意义；进一步在建立的SK-BR-3R 小鼠肿瘤模型中观察到了曲妥珠联合
NSC74859治疗组显示了比曲妥珠或NSC 74859 单独使用时更显著的抑瘤效果。最后，免疫印迹实验显示了曲妥珠和NSC74859
联合处理显著降低了SK-BR-3R细胞的HER2，STAT3 及AKT 的磷酸化水平。结论：曲妥珠单抗联合NSC 74859 使用可显著抑
制曲妥珠耐药的乳腺癌细胞SK-BR-3R的生长，其机制可能是药物协同抑制了对肿瘤生长重要的PI3K/AKT 信号通路。本研究可
为临床上治疗曲妥珠耐药的乳腺癌提供参考。 |
| 英文摘要: |
| Objective:To evaluate the growth inhibitory effects of of trastuzumab-resistant SK-BR-3R cells with combination of
trastuzumab and NSC 74859 and further explore the mechanisminvolved.Methods:Trastuzumab-resistant SK-BR-3 cells was characterized
and cell proliferation of SK-BR-3R upon treatment with trastuzumab, NSC 74859 or trastuzumab plus NSC 74859 were evaluated
by MTT assay. Subsequently, nude mice bearing subcutaneous SK-BR-3R cells xenograft tumor model was set up to evaluate the tumor
growth inhibition upon combinational treatment. Additionally, the levels of phosphorylated HER2, STAT3 and AKT were detected by
western blot assay.Results:Trastuzumab-resistant SK-BR-3 cell line were obtained and characterized by MTT assay. Next, Trastuzumab
(50 nmol/L) plus NSC 74859 (50 umol/L) exhibited significant inhibitory effect compared with either agent alone by MTT assay, showing
statistical difference; Furthermore, combinatorial treatment with trastuzumab plus NSC 74859 resulted in a significant benefit over either
agent alone in SK-BR-3R xenograft models. Finally, combined treatment of trastuzumab and NSC 74859 suppressed HER2, STAT3
and AKT phosphorylation in SK-BR-3R cells.Conclusion:Combination treatment of trastuzumab with NSC 74859 markedly inhibited
the growth of SK-BR-3R cells. Suppression of PI3K/AKT pathway in SK-BR-3R cells could explain the inhibitory effects upon combinational
treatment. To conclude, this study will provide a new regimen for treating the trastuzumab-resistant breast cancer in clinics. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
